Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Modesto

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Gastroenterology|February 14, 2022
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studiesCharlie W Lees, J Jasper Deuring, Michael Chiorean, et al.
Digestive Diseases and Sciences|February 4, 2023
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative ColitisGary R Lichtenstein, Benjamin L Cohen, Leonardo Salese, et al.
Journal of Medical Economics|December 21, 2019
Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costsAxel Dignass, John Waller, Joseph C Cappelleri, et al.
The American Journal of Gastroenterology|March 18, 2008
The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean areaMaria Concetta Renda, Ambrogio Orlando, Giuseppe Civitavecchia, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 8, 2021
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure StatusWilliam J Sandborn, Laurent Peyrin-Biroulet, Ala I Sharara, et al.
BMJ Open Gastroenterology|September 17, 2020
Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitisMatthew J Brookes, John Waller, Joseph C Cappelleri, et al.
Inflammatory Intestinal Diseases|January 27, 2022
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource UseDanielle Bargo, Theo Tritton, Joseph C Cappelleri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 1, 2024
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With EtrasimodFernando Magro, Laurent Peyrin-Biroulet, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Therapeutic Advances in Gastroenterology|November 11, 2024
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trialsCharlie W Lees, Joana Torres, Yvette Leung, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Gastroenterology|February 14, 2022
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studiesCharlie W Lees, J Jasper Deuring, Michael Chiorean, et al.
Digestive Diseases and Sciences|February 4, 2023
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative ColitisGary R Lichtenstein, Benjamin L Cohen, Leonardo Salese, et al.
Journal of Medical Economics|December 21, 2019
Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costsAxel Dignass, John Waller, Joseph C Cappelleri, et al.
The American Journal of Gastroenterology|March 18, 2008
The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean areaMaria Concetta Renda, Ambrogio Orlando, Giuseppe Civitavecchia, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 8, 2021
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure StatusWilliam J Sandborn, Laurent Peyrin-Biroulet, Ala I Sharara, et al.
BMJ Open Gastroenterology|September 17, 2020
Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitisMatthew J Brookes, John Waller, Joseph C Cappelleri, et al.
Inflammatory Intestinal Diseases|January 27, 2022
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource UseDanielle Bargo, Theo Tritton, Joseph C Cappelleri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 1, 2024
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With EtrasimodFernando Magro, Laurent Peyrin-Biroulet, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Therapeutic Advances in Gastroenterology|November 11, 2024
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trialsCharlie W Lees, Joana Torres, Yvette Leung, et al.
Pageof 5